ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease and rheumatoid arthritis (RA)"

  • Abstract Number: 963 • 2015 ACR/ARHP Annual Meeting

    Ectopic Lymphoid Tissue in the Lung Is Associated with Serum Rheumatoid Arthritis-Related Autoantibodies Even in Absence of Clinically Apparent Rheumatoid Arthritis

    Lindsay E. Brown1, M. Kristen Demoruelle2, Mark C. Parish3, Marie L. Feser2, Peter B. Sachs4, David E. Heinz5, Carlyne D. Cool1 and Kevin D. Deane6, 1University of Colorado School of Medicine, Aurora, CO, 2Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 3Rheumatology, University of Colorado Anschutz Medical Campus, Aurora, CO, 4Department of Radiology, University of Colorado School of Medicine, Aurora, CO, 5Pathology, University of Colorado School of Medicine, Aurora, CO, 6Division of Rheumatology, U Colo Denver, Aurora, CO

    Background/Purpose: Lung disease has been associated with elevations of RA and Sjogren's-related autoantibodies (Abs), even in the absence of extrathoracic features of these diseases (Fischer…
  • Abstract Number: 1337 • 2015 ACR/ARHP Annual Meeting

    Pulmonary Computed Tomography Changes in Patients with Rheumatoid Arthritis

    Alexandra Balbir-Gurman1, Ludmila Guralnik2, Mordehai Yigla3, Yolanda Braun-Moscovici4, Anna Astrahan5 and Emilia Hardak6, 1B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel, 2Department of Diagnostic Imaging, Rambam Health Care Campus, The Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel, 3Division of Pulmonary Medicine, Rambam Health Care Campus, The Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel, 4B Shine Department of Rheumatology, Rambam Health Care Campus,. Rappaport Faculty of Medicine, Technion, Haifa, Israel, 5Rappaport Faculty of Medicine-Technion, Israeli Institute of Technology, Haifa, Israel, 6Pulmonary Institute, Rambam Health Care Campus; Rappaport Faculty of Medicine-Technion, Israeli Institute of Technology, Haifa, Israel

    Background/Purpose: Lung involvement in RA it is often diagnosed in advanced stage. Chest CT is the main modality for assessment of ILD. To analyze chest…
  • Abstract Number: 1599 • 2015 ACR/ARHP Annual Meeting

    Clinical Characteristics of Interstitial Lung Disease (ILD) in Rheumatoid Arthritis (RA) Patients in High Resolutional CT (HRCT) and Titer of Anti Citrullinated Peptide Antibodies (anti-CCP2)

    Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: To investigate clinical characteristics of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. And to analyze whether high resolutional CT (HRCT) and anti…
  • Abstract Number: 1366 • 2014 ACR/ARHP Annual Meeting

    Outcomes of Interstitial Lung Disease Associated with Rheumatoid Arthritis in High Volume Referral Centers

    Megan Krause1, Amish Dave2, Cynthia S. Crowson3, Arun K. Chandran1, C. John Michet III1, Paul F. Dellaripa4 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Health Sciences Research, Mayo Clinic, Rochester, MN, 4Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: To describe the characteristics and morbidity and mortality impact of interstitial lung disease in rheumatoid arthritis (RA). Methods: A retrospective review was performed at…
  • Abstract Number: 472 • 2014 ACR/ARHP Annual Meeting

    Abatacept Can be Used Safely for RA Patients with Interstitial Lung Disease

    Shinji Motojima1, Tamao Nakashita2, Akira Jibatake3 and Katsutoshi Ando4, 1[email protected], Kameda Medical Center, Kamogawa City, Japan, 2[email protected], Kameda Medical Center, Kamogawa-city, Japan, 3Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, 4Depertment of Respiratoly Medicine, Juntendo university, tokyo, Japan

    Background/Purpose : Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of…
  • Abstract Number: 2457 • 2014 ACR/ARHP Annual Meeting

    Anti-Major Histocompatibility Complex Class I-Related Chain a (MICA) Antibodies in Rheumatoid Arthritis Patients with Interstitial Lung Disease

    Hiroshi Furukawa1, Shomi Oka1, Kota Shimada2, Akiko Komiya1, Naoshi Fukui1, Naoyuki Tsuchiya3 and Shigeto Tohma1, 1Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 3Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated RA-associated ILD (RA-ILD) that influences the prognosis of the disease.…
  • Abstract Number: 1907 • 2014 ACR/ARHP Annual Meeting

    Clinical Evaluation of Anti-Aminoacyl tRNA Synthase Antibodies in Rheumatoid Arthritis Patients

    Masakazu Matsushita1, Ken Yamaji1, Naoto Tamura2 and Yoshinari Takasaki3, 1Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Anti-Jo-1 is an autoantibody that is specifically detected in the blood sera of patients with polymyositis/dermatomyositis (PM/DM). The corresponding antigen is known to be…
  • Abstract Number: 1404 • 2014 ACR/ARHP Annual Meeting

    Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis

    Muhammad Imran1, Shanley O'brien2, Mark Hamblin3 and Mehrdad Maz4, 1Rheumatology, University of Kansas Medical Center, Kansas City, KS, 2Internal Medicine, Kansas University Medical Center, Kansas city, MO, 3Pulmonary and Critical Care Medicine, ILD Clinic, Kansas University Medical Center, Kansas city, MO, 4Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS

    Background/Purpose:   Interstitial lung disease (ILD) can be idiopathic or associated with underlying etiologies including rheumatoid arthritis (RA). The purpose of this study is to determine…
  • Abstract Number: 1377 • 2014 ACR/ARHP Annual Meeting

    Anti-Citrullinated Peptide Antibody Titers and the Prevalence of Interstitial Lung Disease in Patients with and without Rheumatoid Arthritis

    Chase Correia1, Melissa R. Bussey2, Brittany Panico1, Rong Guo3 and Rochella A. Ostrowski4, 1Internal Medicine, Loyola University Medical Center, Chicago, IL, 2Rheumatology, Division of Rheumatology, Loyola University Medical Center, Maywood, IL, 3Loyola University Medical Center, Chicago, IL, 4Rheumatology, Loyola University Medical Center, Maywood, IL

    Background/Purpose:   Rheumatoid arthritis (RA) is a multisystem inflammatory disease characterized by a symmetric, destructive polyarthritis.  Interstitial lung disease (ILD) is an extra-articular manifestation that…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology